Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, von Bredow D, von Krempelhuber A, Roesch S, Virgin G, Arndtz-Wiedemann N, Meyer TP, Schmidt D, Nichols R, Young P, Chaplin P.

PLoS One. 2015 Oct 6;10(10):e0138348. doi: 10.1371/journal.pone.0138348. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0142802. Hurley, Yadira [corrected to Hurley, Maria Yadira].

2.

Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.

Knitlova J, Hajkova V, Voska L, Elsterova J, Obrova B, Melkova Z.

PLoS One. 2014 Dec 8;9(12):e114374. doi: 10.1371/journal.pone.0114374. eCollection 2014.

3.

Public health emergency planning for children in chemical, biological, radiological, and nuclear (CBRN) disasters.

Bartenfeld MT, Peacock G, Griese SE.

Biosecur Bioterror. 2014 Jul-Aug;12(4):201-7. doi: 10.1089/bsp.2014.0036. Epub 2014 Jul 11.

4.

Social transfer of pathogenic fungus promotes active immunisation in ant colonies.

Konrad M, Vyleta ML, Theis FJ, Stock M, Tragust S, Klatt M, Drescher V, Marr C, Ugelvig LV, Cremer S.

PLoS Biol. 2012;10(4):e1001300. doi: 10.1371/journal.pbio.1001300. Epub 2012 Apr 3.

5.

Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain.

Lu B, Yu W, Huang X, Wang H, Liu L, Chen Z.

J Biomed Biotechnol. 2011;2011:970424. doi: 10.1155/2011/970424. Epub 2011 Jun 20.

6.

Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Soi RK, Rurangirwa FR, McGuire TC, Rwambo PM, DeMartini JC, Crawford TB.

Clin Vaccine Immunol. 2010 Dec;17(12):1842-9. doi: 10.1128/CVI.00220-10. Epub 2010 Sep 28.

7.

Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment.

Hammarlund E, Lewis MW, Hanifin JM, Simpson EL, Carlson NE, Slifka MK.

Vaccine. 2008 Jan 17;26(3):430-9. Epub 2007 Nov 29.

8.

Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.

García AD, Meseda CA, Mayer AE, Kumar A, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2007 Aug;14(8):1032-44. Epub 2007 Jun 27.

9.

Lack of transmission of vaccinia virus.

Stark JH, Frey SE, Blum PS, Monath TP.

Emerg Infect Dis. 2006 Apr;12(4):698-700. No abstract available.

10.

Smallpox vaccine: the good, the bad, and the ugly.

Belongia EA, Naleway AL.

Clin Med Res. 2003 Apr;1(2):87-92. Review.

11.
12.
13.
14.

Smallpox vaccinations: the risks and the benefits.

Conti R.

Issue Brief (Commonw Fund). 2003 Apr;(620):1-9. No abstract available.

Supplemental Content

Support Center